Published online Dec 20, 2018. doi: 10.5306/wjco.v9.i8.188
Peer-review started: June 17, 2018
First decision: July 19, 2018
Revised: August 24, 2018
Accepted: November 4, 2018
Article in press: November 4, 2018
Published online: December 20, 2018
Processing time: 188 Days and 17.8 Hours
Core tip: Targeting Survivin for treatment of cancer is an emerging trend in cancer immunotherapy. In this study we optimized the dose of recombinant full-length Survivin for tumor growth inhibition. Since luteinizing hormone-releasing hormone (LHRH) is also known to support breast cancer in case of premenopausal women, we combined recombinant LHRH fusion protein with Survivin and Mycobacterium indicus pranii and obtained a positive anti-tumor response. We report our results of using recombinant Survivin protein and LHRH fusion protein as potential vaccine antigens for immunotherapy of murine model of breast cancer which was developed by injecting 4T-1 mammary cell line in syngeneic Balb/c mice. Immunized mice challenged with syngeneic 4T-1 cells exhibited suppression of tumor growth and metastasis in lungs in comparison to control mice.